Literature DB >> 3881501

Effect of beclomethasone dipropionate on bronchial responsiveness to histamine in controlled nonsteroid-dependent asthma.

G Ryan, K M Latimer, E F Juniper, R S Roberts, F E Hargreave.   

Abstract

We investigated the possibility that corticosteroids can reduce bronchial responsiveness to histamine by mechanisms other than change in airway caliber. Ten adult asthmatic subjects were selected because their symptoms were controlled by bronchodilators alone, they had no recent respiratory infection or allergen exposure that might have temporarily altered responsiveness, their spirometry was more than 70% predicted, and they had a range of histamine bronchial hyperresponsiveness. They received, in random order and double-blind manner, beclomethasone dipropionate (400 micrograms daily) or placebo for 4 wk and then, after a 2-week washout period, they crossed over to the other treatment for 4 wk. Treatment with beclomethasone induced a small but significant reduction in bronchial responsiveness to histamine (p = 0.014). Although the improvement was too small to be considered of clinical significance, its importance lies in the mechanisms by which it was produced. Part of the improvement was related to improvement in airway caliber, but, even when the data was adjusted for this, there was still a significant difference between beclomethasone and placebo treatment (p = 0.018). The results suggest that regular treatment with corticosteroids can alter bronchial responsiveness through mechanisms other than change in airway caliber.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881501     DOI: 10.1016/0091-6749(85)90007-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

1.  Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis.

Authors:  P M van Grunsven; C P van Schayck; J Molema; R P Akkermans; C van Weel
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 2.  Management of asthma in pre-school children.

Authors:  T P McCarthy; W Lenney
Journal:  Br J Gen Pract       Date:  1992-10       Impact factor: 5.386

3.  Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease.

Authors:  B Auffarth; D S Postma; J G de Monchy; T W van der Mark; M Boorsma; G H Koëter
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

Review 4.  The pharmacology of airway hyperresponsiveness and inflammation.

Authors:  R Pauwels
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 2. Effect on antigen-induced dual asthmatic response and infiltration of leukocytes into airways in actively sensitized conscious guinea pigs.

Authors:  T Sugasawa; N Imanishi; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

6.  The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma.

Authors:  J P Finnerty; S T Holgate; J P Rihoux
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

7.  Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis.

Authors:  K H Carlsen; J Leegaard; S Larsen; I Orstavik
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

8.  Peripheral blood eosinophil counts and bronchial responsiveness.

Authors:  K J Taylor; A R Luksza
Journal:  Thorax       Date:  1987-06       Impact factor: 9.139

9.  Bronchial hyperresponsiveness following acute severe asthma.

Authors:  A Rabbat; J P Laaban; E Orvoën-Frija; M F Doré; A Achkar; J Rochemaure
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

10.  The effect of platelet activating factor on nasal hypersensitivity.

Authors:  M Andersson; U Pipkorn
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.